2592 — Cloudbreak Pharma Cashflow Statement
0.000.00%
- HK$6.99bn
- HK$9.58bn
- $10.00m
Annual cashflow statement for Cloudbreak Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -66.8 | -129 | -98.3 |
| Depreciation | |||
| Non-Cash Items | 44.4 | 105 | 72.3 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 1.96 | 0.971 | -1.8 |
| Change in Prepaid Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -20.1 | -22.5 | -26.5 |
| Capital Expenditures | -0.778 | -2.21 | -0.155 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -29 | 59.6 | 9.53 |
| Sale/Maturity of Investment | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -29.8 | 57.4 | 9.37 |
| Financing Cash Flow Items | -14.1 | -0.413 | -0.106 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | -14.3 | 2.05 | -0.457 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -64.7 | 36.7 | -17.8 |